Extended Data Fig. 10: NeoAGNAS-specific cytotoxicity by NEJGNAS-specific TCR-transduced CD8+ T-cells.
From: Tumour-wide RNA splicing aberrations generate actionable public neoantigens
A. NeoAGNAS-specific TCR-transduced (colored), or non-transduced (gray) CD8+ T-cells cultured against GBM102 (left), RPMI-7951 (center), and WM-266-4 (right) on the xCELLigence plate platform. The assay was performed at an E:T ratio of 2:1. Cytotoxic killing was determined as the reduction of cell index compared to the control co-cultures with non-transduced CD8 + T-cells (gray) or no CD8+ T-cell introduction (black) at a given time point. (n = 3) B. Representative flow gating of surface CD137 expression in non-transduced (top) and TCR-transduced (bottom) CD8 + T-cells co-cultured against cancer cell lines. C. Gating strategy for flow cytometry experiments. Further statistical details are found in Supplementary Table 3. D. Bar plot of the surface expression of CD137 on NeoAGNAS-TCR-transduced (red) or non-transduced (gray) CD8+ T-cells when cultured with tumor cell lines (n = 3). E-F. ELISA readout of secreted IFNγ (E), IL-2 (F), and TNFα (G) by NeoAGNAS-TCR-transduced (colored) or non-transduced (gray) CD8+ T-cells when cultured with tumor cell lines (n = 3). Further statistical details are found in Supplementary Table 3.
